- $7.69m
- $21.54m
- $8.51m
- 38
- 40
- 57
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.9 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -102.44% | ||
| Return on Equity | -310.98% | ||
| Operating Margin | -254.8% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.04 | 0.93 | 1.68 | 5.64 | 8.51 | 14.18 | 23.66 | 62.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.
Directors
- Sarit Firon NEC (54)
- Ofer Haviv PRE (55)
- Dorit Kreiner CFO (50)
- Ido Dor CEX (45)
- Douglas Eisner CEX (40)
- Elran Haber CEX (41)
- Arnon Heyman CEX (44)
- Mark Kapel EVP (44)
- Eyal Emmanuel CSO (47)
- Ziv Kop IND (50)
- Adrian Percy IND (55)
- Leon Recanati IND (73)
- Oded Shoseyov IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 10th, 1999
- Public Since
- June 11th, 2007
- No. of Shareholders
- 3
- No. of Employees
- 117
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 6,514,589
- Address
- 13 Gad Feinstein Street, Park Rehovot, REHOVOT, 7638517
- Web
- https://evogene.com/
- Phone
- +972 89311900
- Contact
- Kenny Green
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for EVGN
Evogene Ltd Annual Shareholders Meeting
Q2 2025 Evogene Ltd Earnings Release
Similar to EVGN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Evogene share price?
As of Today at 20:34 UTC, shares in Evogene are trading at $1.18. This share price information is delayed by 15 minutes.
How has the Evogene share price performed this year?
Shares in Evogene last closed at $1.18 and the price had moved by -83.27% over the past 365 days. In terms of relative price strength the Evogene share price has underperformed the S&P500 Index by -84.92% over the past year.
What are the analyst and broker recommendations for Evogene?
The overall consensus recommendation for Evogene is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Evogene dividend yield?
Evogene does not currently pay a dividend.
Does Evogene pay a dividend?
Evogene does not currently pay a dividend.
When does Evogene next pay dividends?
Evogene does not currently pay a dividend.
How do I buy Evogene shares?
To buy shares in Evogene you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evogene?
As of the previous close price of $1.18, shares in Evogene had a market capitalisation of $7.69m.
Where are Evogene shares listed?
Here are the trading details for Evogene:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EVGN
What kind of share is Evogene?
Based on an overall assessment of its quality, value and momentum Evogene is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evogene share price forecast for 2025?
The analyst consensus target price for shares in Evogene is $5.54. That is 369.58% above the last closing price of $1.18.
Analysts covering Evogene currently have a consensus Earnings Per Share (EPS) forecast of -$2.16 for the next financial year.
Find out moreWhat is the trend in the Evogene share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evogene. Over the past six months, its share price has underperformed the S&P500 Index by -47.08%.
As of the last closing price of $1.18, shares in Evogene were trading -47.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evogene PE Ratio?
The Evogene PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evogene?
Evogene's management team is headed by:
- Sarit Firon - NEC
- Ofer Haviv - PRE
- Dorit Kreiner - CFO
- Ido Dor - CEX
- Douglas Eisner - CEX
- Elran Haber - CEX
- Arnon Heyman - CEX
- Mark Kapel - EVP
- Eyal Emmanuel - CSO
- Ziv Kop - IND
- Adrian Percy - IND
- Leon Recanati - IND
- Oded Shoseyov - IND